Keyphrases
3 Fatty Acids
18%
Abdominal Fat
22%
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
18%
Acute Coronary Syndrome
12%
Anacetrapib
33%
Apolipoprotein B (Apo B)
25%
Apolipoprotein B-100
17%
Bone Fracture
13%
Bone Loss
12%
Bone Mass
14%
Bone Mineral Density
19%
Cardiovascular Disease
25%
Cardiovascular Events
24%
Cardiovascular Mortality
18%
Cardiovascular Outcomes
52%
Cholesterol Absorption Inhibitor
23%
Confidence Interval
38%
Cystic Fibrosis
19%
Diabetes
41%
Diabetes Prevention
13%
Dysglycemia
35%
End-stage Lung Disease
13%
Fasting Plasma Glucose
20%
Fractional Clearance
15%
Glargine
22%
Hazard Ratio
42%
High-density Lipoprotein Cholesterol (HDL-C)
12%
HIV Patients
17%
Impaired Fasting Glucose
43%
Impaired Glucose Tolerance
40%
Insulin Glargine
26%
Insulin Resistance
17%
Insulin Sensitivity
15%
International Trial
22%
Lumbar Spine
20%
Lung Transplantation
22%
Osteoporosis
20%
Placebo
63%
Placebo Groups
17%
Production Rate
14%
Ramipril
25%
Randomized Double-blind
13%
Recombinant Human Growth Hormone (r-hGH)
22%
Rosiglitazone
60%
Systolic Blood Pressure
14%
Type 2 Diabetes Mellitus (T2DM)
99%
Type 2 Diabetic Patients
42%
Vitamin D
20%
Vitamin D Deficiency
16%
VLDL-Triglycerides
22%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
12%
Adiponectin
11%
Anacetrapib
33%
Apolipoprotein A
11%
Apolipoprotein B
11%
Atrial Fibrillation
11%
Cardiovascular Disease
46%
Cardiovascular Risk
24%
Cerebrovascular Accident
17%
Cholesterol Ester Transfer Protein
22%
Congestive Heart Failure
14%
Coronary Artery Atherosclerosis
11%
Cystic Fibrosis
22%
Darapladib
11%
Dysglycemia
35%
Edoxaban
11%
Exendin 4
11%
Fatty Acid
18%
Glibenclamide Plus Metformin
11%
Glucocorticoid
22%
Glycosylated Hemoglobin
21%
Heart Infarction
15%
High Density Lipoprotein
11%
HIV
22%
Human Growth Hormone
22%
Hypovitaminosis D
17%
Impaired Glucose Tolerance
44%
Inflammation
12%
Insulin Glargine
27%
Insulin Resistance
15%
Lipoprotein
11%
Lorcaserin
11%
Lung Disease
25%
Monotherapy
13%
Non Insulin Dependent Diabetes Mellitus
100%
Obesity
18%
Omega-3 Fatty Acid
24%
Pioglitazone
11%
Placebo
93%
PPAR Agonist
11%
Ramipril
22%
Randomized Clinical Trial
12%
Remission
11%
Rosiglitazone
56%
Sitagliptin
11%
Tablet
11%
Triacylglycerol
24%
Very Low Density Lipoprotein
22%
Vitamin D
22%
Vitamin D Deficiency
17%
Medicine and Dentistry
Abdominal Fat
22%
Adiponectin
11%
Adipose Tissue
6%
Apoplexy
7%
Arm
7%
Atherosclerosis
15%
Bone Density
5%
Cardiovascular Disease
25%
Cardiovascular Disease Prevention
11%
Cardiovascular Risk
14%
Cardiovascular System
67%
Congestive Heart Failure
9%
Coronary Artery Disease
11%
Diabetes
54%
Diabetes Prevention
12%
Disease
16%
Dysglycemia
24%
Endocrine Disease
11%
Fracture
11%
Glipizide
5%
Hazard Ratio
14%
Hemoglobin A1c
5%
Human Growth Hormone
22%
Human Immunodeficiency Virus
29%
Human Immunodeficiency Virus Infection
11%
Hypoglycemia
7%
Impaired Fasting Glucose
21%
Impaired Glucose Tolerance
26%
Insulin Glargine
24%
Insulin Resistance
13%
Isotopes of Calcium
12%
Lean Body Weight
7%
Lipid Storage
22%
Lorcaserin
11%
Lung Transplantation
11%
Malignant Neoplasm
9%
Maturity Onset Diabetes of the Young
38%
Myocardial Infarction
7%
Obesity
11%
Omega-3 Fatty Acid
12%
Osteolysis
11%
Patient with Diabetes
14%
Patient with Type 2 Diabetes
16%
Placebo
47%
Polycystic Ovarian Syndrome
11%
Ramipril
13%
Rosiglitazone
47%
Sitagliptin
11%
Vitamin D
12%
Water-Electrolyte Imbalance
11%